Acute pulmonary embolism in a patient with COVID-19 pneumonia

Cellina, Michaela; Oliva, Giancarlo

doi:10.1016/j.diii.2020.04.001

Cited by 37 publications

(35 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…High prevalence of VTE characterizes patients with SARS-CoV-2 infection and is associated with adverse outcome, mainly due to ventilation-perfusion mismatch secondary to pulmonary embolism (PE). [10][11][12][13] Noteworthy, PE has been found as first sign of SARS-CoV2 infection even in patients with no early evidence of virus at nasal-pharyngeal swab-but later recognized by further swab, serology testing or PCR on bronchoalveolar lavage fluid- [14][15][16] as also observed in our experience (IRCCS Ospedale Policlinico San Martino, Genoa, Italy). Hospitalized patients should then have coagulation tests performed at admission in order to identify stratify risk in swab-positive patients or even identify those yet 'unrecognized'.…”

supporting

confidence: 76%

SARS‐CoV‐2: What is known and what there is to know—Focus on coagulation and lipids

Carbone

Montecucco

Twickler

2020

Eur J Clin Investigation

View full text Add to dashboard Cite

supporting

confidence: 76%

SARS‐CoV‐2: What is known and what there is to know—Focus on coagulation and lipids

Carbone

Montecucco

Twickler

2020

Eur J Clin Investigation

View full text Add to dashboard Cite

“…A diverse range of cardiovascular disease has been reported in patients with COVID-19 which encompasses acute myocarditis (including acute lymphocytic myocarditis) [53], fulminant myocarditis [15,24,37,[54][55][56], acute myocardial infarction type 2 [7], acute myopericarditis [46], acute pulmonary embolism [57][58][59][60], cardiac tamponade [46], cardiogenic shock [61,62], cardiomyopathy [63], heart failure, pericardial effusion, pulmonary hypertension, reverse Takotsubo cardiomyopathy [64], and right ventricular dysfunction [62,65].…”

Section: Systematic Review Spectrum Of Newly Developed Cardiovascularmentioning

confidence: 99%

Cardiovascular disease in COVID-19: a systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool

et al. 2020

View full text Add to dashboard Cite

Background: Coronavirus disease 2019 (COVID-19) pandemic has drastically affected global health. Despite several studies, there is yet a dearth of data regarding the mechanisms of cardiac injury, clinical presentation, risk factors, and treatment of COVID-19-associated cardiovascular disease. This systematic review and meta-analysis is aimed at defining the clinical, electrocardiographic, and pathologic spectrum of cardiovascular disease (CVD), frequency of elevated cardiac and inflammatory biomarkers, and their frequency and relationship with severity of the disease and mortality in COVID-19 patients and to develop a triage risk stratification tool (TRST) that can serve as a guide for the timely recognition of the high-risk patients and mechanism-targeted therapy. We conducted an online search in databases of PubMed and Embase to identify relevant studies. Data selection was in concordance with PRISMA guidelines. Results were presented as pooled frequencies, odds ratio, standardized mean difference (SMD), and forest and funnel plots. Results: We gathered a total of 54 studies and included 35 of them in our meta-analysis. Acute cardiac injury occurred in more than 25% of cases, mortality was 20 times higher, and admission to intensive care unit increased by 13.5 times. Hypertension was the most common pre-existing comorbidity with a frequency of 29.2%, followed by diabetes mellitus (13.5%). The deceased group of patients had higher cardiac and inflammatory biomarkers, with statistically significant SMD, compared with survivors. Pediatric patients were predominantly mildly affected. However, less frequently, the presentation was very similar to Kawasaki disease or Kawasaki shock syndrome. This latter presentation hass been called as multisystem inflammatory syndrome in children (MIS-C). Conclusions: There is a wide spectrum of cardiac involvement in COVID-19 patients, and hence a Triage Risk Stratification Tool can serve as a guide for the timely recognition of the high-risk patients and mechanism-targeted therapy.

show abstract

“…Complications reported with Severe Acute Respiratory Syndrome (SARS) caused by coronavirus in 2003-2004 included deep venous thrombosis (DVT), PE, and diffuse intravascular coagulation (DIC). Frequent pulmonary emboli in necropsy series of SARS patients were reported as well [2,3].…”

Section: Discussionmentioning

confidence: 96%

Coronavirus Disease 2019-Associated Bilateral Massive Pulmonary Emboli Caused Death in a Healthy 35-Year-Old Patient

Sbihi¹,

Manasrah²,

Kosti³

et al. 2020

Cureus

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) infection was first reported in December 2019. Within three months, the virus caused a global pandemic that has affected the whole world's dynamics. Many causes of death due to COVID-19 infection have been identified, involving but not limited to atypical acute respiratory distress syndrome, hypercoagulability, renal failure, and a proinflammatory cytokine storm, often associated with multiorgan failure. We report the case of a young, previously healthy patient who developed massive pulmonary emboli due to COVID-19 infection, resulting in death.

show abstract

Acute pulmonary embolism in a patient with COVID-19 pneumonia

Cited by 37 publications

References 3 publications

SARS‐CoV‐2: What is known and what there is to know—Focus on coagulation and lipids

SARS‐CoV‐2: What is known and what there is to know—Focus on coagulation and lipids

Cardiovascular disease in COVID-19: a systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool

Coronavirus Disease 2019-Associated Bilateral Massive Pulmonary Emboli Caused Death in a Healthy 35-Year-Old Patient

Contact Info

Product

Resources

About